BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25138574)

  • 1. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial.
    Esteghamati A; Rezvani S; Khajeh E; Ebadi M; Nakhjavani M; Noshad S
    J Endocrinol Invest; 2014 Dec; 37(12):1211-8. PubMed ID: 25138574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: a randomized clinical trial.
    Esteghamati A; Noshad S; Rabizadeh S; Ghavami M; Zandieh A; Nakhjavani M
    Regul Pept; 2013 Mar; 182():1-6. PubMed ID: 23328000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
    Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
    Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
    Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
    Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: a randomized clinical trial.
    Mirmiranpour H; Mousavizadeh M; Noshad S; Ghavami M; Ebadi M; Ghasemiesfe M; Nakhjavani M; Esteghamati A
    J Diabetes Complications; 2013; 27(5):501-7. PubMed ID: 23891275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin.
    Maffioli P; Fogari E; D'Angelo A; Perrone T; Derosa G
    Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1113-22. PubMed ID: 23524525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pioglitazone and linagliptin on glycemic control, lipid profile and hs-CRP in metformin-treated patients with type 2 diabetes: a comparative study.
    Zamani B; Tabatabizadeh SM; Gilasi H; Yazdani S
    Horm Mol Biol Clin Investig; 2023 Dec; 44(4):385-391. PubMed ID: 38143260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse Association of Peripheral Orexin-A with Insulin Resistance in Type 2 Diabetes Mellitus: A Randomized Clinical Trial.
    Zarifkar M; Noshad S; Shahriari M; Afarideh M; Khajeh E; Karimi Z; Ghajar A; Esteghamati A
    Rev Diabet Stud; 2017; 14(2-3):301-310. PubMed ID: 29145540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control.
    Seufert J
    Curr Med Res Opin; 2006; 22 Suppl 2():S39-48. PubMed ID: 16914074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pioglitazone versus metformin on cardiovascular risk markers in type 2 diabetes.
    Genovese S; De Berardis G; Nicolucci A; Mannucci E; Evangelista V; Totani L; Pellegrini F; Ceriello A
    Adv Ther; 2013 Feb; 30(2):190-202. PubMed ID: 23359066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti oxidant potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond their anti glycemic effect.
    Singh RK; Gupta B; Tripathi K; Singh SK
    Diabetes Metab Syndr; 2016; 10(2):102-4. PubMed ID: 26341927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
    Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
    Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus.
    Kanazawa I; Yamamoto M; Yamaguchi T; Sugimoto T
    Exp Clin Endocrinol Diabetes; 2011 Jun; 119(6):362-5. PubMed ID: 21472665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.